Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

WVVI vs NBY vs AYTU vs PRPH vs PAHC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WVVI
Willamette Valley Vineyards, Inc.

Beverages - Wineries & Distilleries

Consumer DefensiveNASDAQ • US
Market Cap$14M
5Y Perf.-52.1%
NBY
NovaBay Pharmaceuticals, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$11M
5Y Perf.-100.0%
AYTU
Aytu BioPharma, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$16M
5Y Perf.-99.2%
PRPH
ProPhase Labs, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5M
5Y Perf.-96.2%
PAHC
Phibro Animal Health Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.75B
5Y Perf.+64.7%

WVVI vs NBY vs AYTU vs PRPH vs PAHC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WVVI logoWVVI
NBY logoNBY
AYTU logoAYTU
PRPH logoPRPH
PAHC logoPAHC
IndustryBeverages - Wineries & DistilleriesBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$14M$11M$16M$5M$1.75B
Revenue (TTM)$37M$3M$63M$1M$1.46B
Net Income (TTM)$-1M$3M$-24M$-42M$92M
Gross Margin60.5%54.6%66.0%191.4%31.9%
Operating Margin-2.4%-273.0%-13.9%-25.0%11.6%
Forward P/E14.2x
Total Debt$15.52B$2M$23M$25M$762M
Cash & Equiv.$411M$430K$31M$678K$68M

WVVI vs NBY vs AYTU vs PRPH vs PAHCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WVVI
NBY
AYTU
PRPH
PAHC
StockMay 20May 26Return
Willamette Valley V… (WVVI)10047.9-52.1%
NovaBay Pharmaceuti… (NBY)1000.0-100.0%
Aytu BioPharma, Inc. (AYTU)1000.8-99.2%
ProPhase Labs, Inc. (PRPH)1003.8-96.2%
Phibro Animal Healt… (PAHC)100164.7+64.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: WVVI vs NBY vs AYTU vs PRPH vs PAHC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NBY and PAHC are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Phibro Animal Health Corporation is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. WVVI and AYTU also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
WVVI
Willamette Valley Vineyards, Inc.
The Income Pick

WVVI ranks third and is worth considering specifically for income & stability.

  • Dividend streak 4 yrs, beta -0.25, yield 100.0%
  • 100.0% yield, 4-year raise streak, vs PAHC's 1.1%, (3 stocks pay no dividend)
Best for: income & stability
NBY
NovaBay Pharmaceuticals, Inc.
The Quality Compounder

NBY carries the broadest edge in this set and is the clearest fit for quality and efficiency.

  • 114.6% margin vs PRPH's -38.7%
  • 93.0% ROA vs PRPH's -63.5%, ROIC -217.0% vs -59.4%
Best for: quality and efficiency
AYTU
Aytu BioPharma, Inc.
The Defensive Pick

AYTU is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.27, current ratio 1.26x
  • Beta 1.27 vs NBY's 2.43
Best for: sleep-well-at-night
PRPH
ProPhase Labs, Inc.
The Healthcare Pick

Among these 5 stocks, PRPH doesn't own a clear edge in any measured category.

Best for: healthcare exposure
PAHC
Phibro Animal Health Corporation
The Growth Play

PAHC is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 27.4%, EPS growth 18.8%, 3Y rev CAGR 11.2%
  • 128.6% 10Y total return vs PRPH's 37.5%
  • Beta 1.38, yield 1.1%, current ratio 2.76x
  • 27.4% revenue growth vs WVVI's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthPAHC logoPAHC27.4% revenue growth vs WVVI's -100.0%
Quality / MarginsNBY logoNBY114.6% margin vs PRPH's -38.7%
Stability / SafetyAYTU logoAYTUBeta 1.27 vs NBY's 2.43
DividendsWVVI logoWVVI100.0% yield, 4-year raise streak, vs PAHC's 1.1%, (3 stocks pay no dividend)
Momentum (1Y)PAHC logoPAHC+125.1% vs PRPH's -58.0%
Efficiency (ROA)NBY logoNBY93.0% ROA vs PRPH's -63.5%, ROIC -217.0% vs -59.4%

WVVI vs NBY vs AYTU vs PRPH vs PAHC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

WVVIWillamette Valley Vineyards, Inc.

Segment breakdown not available.

NBYNovaBay Pharmaceuticals, Inc.
FY 2024
Total Product Revenue
100.0%$10M
AYTUAytu BioPharma, Inc.
FY 2024
Consumer Health
100.0%$16M
PRPHProPhase Labs, Inc.
FY 2024
Consumer Products
100.0%$7M
PAHCPhibro Animal Health Corporation
FY 2025
Vaccines
100.0%$137M

WVVI vs NBY vs AYTU vs PRPH vs PAHC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPAHCLAGGINGPRPH

Income & Cash Flow (Last 12 Months)

PAHC leads this category, winning 4 of 6 comparable metrics.

PAHC is the larger business by revenue, generating $1.5B annually — 1359.6x PRPH's $1M. NBY is the more profitable business, keeping 114.6% of every revenue dollar as net income compared to PRPH's -38.7%. On growth, PAHC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…AYTU logoAYTUAytu BioPharma, I…PRPH logoPRPHProPhase Labs, In…PAHC logoPAHCPhibro Animal Hea…
RevenueTrailing 12 months$37M$3M$63M$1M$1.5B
EBITDAEarnings before interest/tax$2M-$8M-$4M-$22M$220M
Net IncomeAfter-tax profit-$1M$3M-$24M-$42M$92M
Free Cash FlowCash after capex-$3M-$7M-$698,000-$23M$47M
Gross MarginGross profit ÷ Revenue+60.5%+54.6%+66.0%+191.4%+31.9%
Operating MarginEBIT ÷ Revenue-2.4%-2.7%-13.9%-25.0%+11.6%
Net MarginNet income ÷ Revenue-3.3%+114.6%-39.0%-38.7%+6.3%
FCF MarginFCF ÷ Revenue-8.5%-2.5%-1.1%-21.1%+3.2%
Rev. Growth (YoY)Latest quarter vs prior year-10.9%-78.7%-6.5%-71.9%+20.9%
EPS Growth (YoY)Latest quarter vs prior year-94.1%+63.3%-3.0%+54.3%+7.4%
PAHC leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

WVVI leads this category, winning 2 of 3 comparable metrics.
MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…AYTU logoAYTUAytu BioPharma, I…PRPH logoPRPHProPhase Labs, In…PAHC logoPAHCPhibro Animal Hea…
Market CapShares × price$14M$11M$16M$5M$1.7B
Enterprise ValueMkt cap + debt − cash$15.1B$13M$7M$29M$2.4B
Trailing P/EPrice ÷ TTM EPS-4.53x-0.74x-1.14x-0.05x36.27x
Forward P/EPrice ÷ next-FY EPS est.14.23x
PEG RatioP/E ÷ EPS growth rate4.85x
EV / EBITDAEnterprise value multiple15.65x
Price / SalesMarket cap ÷ Revenue1.16x0.23x0.74x1.35x
Price / BookPrice ÷ Book value/share0.00x0.82x0.31x6.15x
Price / FCFMarket cap ÷ FCF41.82x
WVVI leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

PAHC leads this category, winning 4 of 9 comparable metrics.

NBY delivers a 198.5% return on equity — every $100 of shareholder capital generates $198 in annual profit, vs $-6 for PRPH. WVVI carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRPH's 3.34x. On the Piotroski fundamental quality scale (0–9), PAHC scores 5/9 vs PRPH's 1/9, reflecting solid financial health.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…AYTU logoAYTUAytu BioPharma, I…PRPH logoPRPHProPhase Labs, In…PAHC logoPAHCPhibro Animal Hea…
ROE (TTM)Return on equity-1.8%+198.5%-172.1%-6.1%+30.8%
ROA (TTM)Return on assets-1.1%+93.0%-20.0%-63.5%+6.7%
ROICReturn on invested capital-2.6%-2.2%-33.5%-59.4%+9.8%
ROCEReturn on capital employed-3.1%-2.2%-13.3%-75.6%+12.0%
Piotroski ScoreFundamental quality 0–913315
Debt / EquityFinancial leverage0.23x1.21x3.34x2.67x
Net DebtTotal debt minus cash$15.1B$1M-$8M$24M$694M
Cash & Equiv.Liquid assets$411M$430,000$31M$678,000$68M
Total DebtShort + long-term debt$15.5B$2M$23M$25M$762M
Interest CoverageEBIT ÷ Interest expense-0.69x-89.97x-7.96x-7.96x3.64x
PAHC leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PAHC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in PAHC five years ago would be worth $16,597 today (with dividends reinvested), compared to $13 for NBY. Over the past 12 months, PAHC leads with a +125.1% total return vs PRPH's -58.0%. The 3-year compound annual growth rate (CAGR) favors PAHC at 45.9% vs PRPH's -69.4% — a key indicator of consistent wealth creation.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…AYTU logoAYTUAytu BioPharma, I…PRPH logoPRPHProPhase Labs, In…PAHC logoPAHCPhibro Animal Hea…
YTD ReturnYear-to-date-8.6%-93.6%-10.8%-66.7%+16.0%
1-Year ReturnPast 12 months-49.3%+102.8%+104.1%-58.0%+125.1%
3-Year ReturnCumulative with dividends-51.0%-96.5%+40.3%-97.1%+210.4%
5-Year ReturnCumulative with dividends-80.8%-99.9%-97.8%-63.2%+66.0%
10-Year ReturnCumulative with dividends-59.3%-100.0%-100.0%+37.5%+128.6%
CAGR (3Y)Annualised 3-year return-21.2%-67.4%+12.0%-69.4%+45.9%
PAHC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — WVVI and AYTU each lead in 1 of 2 comparable metrics.

WVVI is the less volatile stock with a -0.25 beta — it tends to amplify market swings less than NBY's 2.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AYTU currently trades 80.5% from its 52-week high vs NBY's 1.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…AYTU logoAYTUAytu BioPharma, I…PRPH logoPRPHProPhase Labs, In…PAHC logoPAHCPhibro Animal Hea…
Beta (5Y)Sensitivity to S&P 500-0.25x2.43x1.27x2.28x1.38x
52-Week HighHighest price in past year$7.18$99.75$3.07$1.84$60.08
52-Week LowLowest price in past year$2.49$1.11$1.20$0.07$19.00
% of 52W HighCurrent price vs 52-week peak+40.3%+1.9%+80.5%+6.5%+71.8%
RSI (14)Momentum oscillator 0–10053.542.548.956.860.3
Avg Volume (50D)Average daily shares traded3K595K42K105K302K
Evenly matched — WVVI and AYTU each lead in 1 of 2 comparable metrics.

Analyst Outlook

WVVI leads this category, winning 2 of 2 comparable metrics.

For income investors, WVVI offers the higher dividend yield at 100.00% vs PAHC's 1.11%.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…AYTU logoAYTUAytu BioPharma, I…PRPH logoPRPHProPhase Labs, In…PAHC logoPAHCPhibro Animal Hea…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$49.00
# AnalystsCovering analysts13
Dividend YieldAnnual dividend ÷ price+100.0%+1.1%
Dividend StreakConsecutive years of raises410
Dividend / ShareAnnual DPS$194.20$0.48
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%0.0%
WVVI leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

PAHC leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). WVVI leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallPhibro Animal Health Corpor… (PAHC)Leads 3 of 6 categories
Loading custom metrics...

WVVI vs NBY vs AYTU vs PRPH vs PAHC: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is WVVI or NBY or AYTU or PRPH or PAHC a better buy right now?

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — WVVI or NBY or AYTU or PRPH or PAHC?

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.

0%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — WVVI or NBY or AYTU or PRPH or PAHC?

By beta (market sensitivity over 5 years), Willamette Valley Vineyards, Inc.

(WVVI) is the lower-risk stock at -0. 25β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -1067% more volatile than WVVI relative to the S&P 500. On balance sheet safety, Willamette Valley Vineyards, Inc. (WVVI) carries a lower debt/equity ratio of 23% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — WVVI or NBY or AYTU or PRPH or PAHC?

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — WVVI or NBY or AYTU or PRPH or PAHC?

Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.

7% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — WVVI or NBY or AYTU or PRPH or PAHC?

In this comparison, WVVI (100.

0% yield), PAHC (1. 1% yield) pay a dividend. NBY, AYTU, PRPH do not pay a meaningful dividend and should not be held primarily for income.

07

Is WVVI or NBY or AYTU or PRPH or PAHC better for a retirement portfolio?

For long-horizon retirement investors, Willamette Valley Vineyards, Inc.

(WVVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 25), 100. 0% yield). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WVVI: -59. 3%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between WVVI and NBY and AYTU and PRPH and PAHC?

These companies operate in different sectors (WVVI (Consumer Defensive) and NBY (Healthcare) and AYTU (Healthcare) and PRPH (Healthcare) and PAHC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WVVI is a small-cap income-oriented stock; NBY is a small-cap quality compounder stock; AYTU is a small-cap quality compounder stock; PRPH is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock. WVVI, PAHC pay a dividend while NBY, AYTU, PRPH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

WVVI

Income & Dividend Stock

  • Sector: Consumer Defensive
  • Market Cap > $100B
  • Gross Margin > 36%
  • Dividend Yield > 40.0%
Run This Screen
Stocks Like

NBY

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 68%
Run This Screen
Stocks Like

AYTU

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

PRPH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 114%
Run This Screen
Stocks Like

PAHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform WVVI and NBY and AYTU and PRPH and PAHC on the metrics below

Revenue Growth>
%
(WVVI: -10.9% · NBY: -78.7%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.